Literature DB >> 27349182

Beneficial effects of voglibose administration on body weight and lipid metabolism via gastrointestinal bile acid modification.

Hyun Ju Do1, Youn Sue Lee, Min Jin Ha, Yoonsu Cho, Hana Yi, Yu-Jin Hwang, Geum-Sook Hwang, Min-Jeong Shin.   

Abstract

This study was designed with the goal of examining the effects of voglibose administration on body weight and lipid metabolism and underlying mechanism high fat diet-induced obese mice. Male C57BL/6 mice were randomly assigned to one of four groups: a control diet (CTL), high-fat diet (HF), high-fat diet supplemented with voglibose (VO), and high fat diet pair-fed group (PF). After 12 weeks, the following characteristics were investigated: serum lipid and glucose levels, serum polar metabolite profiles, and expression levels of genes involved in lipid and bile acid metabolism. In addition, pyrosequencing was used to analyze the composition of gut microbiota found in feces. Total body weight gain was significantly lower in the VO group than in the CTL, HF, and PF groups. The VO group exhibited improved metabolic profiles including those of blood glucose, triglyceride, and total cholesterol levels. The 12-week voglibose administration decreased the ratio of Firmicutes to Bacteroidetes found in feces. Circulating levels of taurocholic and cholic acid were significantly higher in the VO group than in the HF and CTL groups. Deoxycholic acid levels tended to be higher in the VO group than in the HF group. Voglibose administration downregulated expression levels of CYP8B1 and HNF4α genes and upregulated those of PGC1α, whereas FXRα was not affected. Voglibose administration elicits changes in the composition of the intestinal microbiota and circulating metabolites, which ultimately has systemic effects on body weight and lipid metabolism in mice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27349182     DOI: 10.1507/endocrj.EJ15-0747

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  9 in total

Review 1.  Role and effective therapeutic target of gut microbiota in NAFLD/NASH.

Authors:  Qun Liu; Shousheng Liu; Lizhen Chen; Zhenzhen Zhao; Shuixian Du; Quanjiang Dong; Yongning Xin; Shiying Xuan
Journal:  Exp Ther Med       Date:  2019-07-17       Impact factor: 2.447

Review 2.  Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus.

Authors:  Wenhui Liu; Zhiying Luo; Jiecan Zhou; Bao Sun
Journal:  Front Cell Infect Microbiol       Date:  2022-05-31       Impact factor: 6.073

3.  Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.

Authors:  Thao T B Cao; Kun-Chang Wu; Jye-Lin Hsu; Chih-Shiang Chang; Chiahung Chou; Chen-Yuan Lin; Yu-Min Liao; Pei-Chun Lin; Liang-Yo Yang; Hsiang-Wen Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-23       Impact factor: 5.555

4.  High Sucrose and Cholic Acid Diet Triggers PCOS-like Phenotype and Reduces Enterobacteriaceae Colonies in Female Wistar Rats.

Authors:  I Made Putra Juliawan; Febie Putra Suwana; Jimmy Yanuar Annas; Muhammad Firman Akbar; Widjiati Widjiati
Journal:  Pathophysiology       Date:  2022-07-08

Review 5.  Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites.

Authors:  Dongmei Wang; Jieying Liu; Liyuan Zhou; Qian Zhang; Ming Li; Xinhua Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-13       Impact factor: 6.055

Review 6.  Effects of Antidiabetic Drugs on Gut Microbiota Composition.

Authors:  Sophie A Montandon; François R Jornayvaz
Journal:  Genes (Basel)       Date:  2017-09-30       Impact factor: 4.096

Review 7.  The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus.

Authors:  Thiquynhnga Nguyen; Min Gong; Song Wen; Xinlu Yuan; Chaoxun Wang; Jianlan Jin; Ligang Zhou
Journal:  J Diabetes Res       Date:  2020-06-16       Impact factor: 4.011

8.  Diet-Induced Obese Mice and Leptin-Deficient Lepob/ob Mice Exhibit Increased Circulating GIP Levels Produced by Different Mechanisms.

Authors:  Eunyoung Lee; Emily L Miedzybrodzka; Xilin Zhang; Ryo Hatano; Junki Miyamoto; Ikuo Kimura; Kosuke Fujimoto; Satoshi Uematsu; Sergio Rodriguez-Cuenca; Antonio Vidal-Puig; Fiona M Gribble; Frank Reimann; Takashi Miki
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

9.  Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis.

Authors:  Hongshan Li; Yingfei Xi; Xin Xin; Huajie Tian; Yiyang Hu
Journal:  Nutr Metab (Lond)       Date:  2020-05-01       Impact factor: 4.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.